Takashi Takahashi

List of Publications by Year in Descending Order

220 papers	22,501 citations	68 h-index	147 g-index
230 ext. papers	24,471 ext. citations	7.3 avg, IF	6.12 L-index

#	Paper	IF	Citations
220	Ferroptosis resistance determines high susceptibility of murine A/J strain to iron-induced renal carcinogenesis. *Cancer Science*, **2021**,	6.9	4
219	CEBP facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation. *Cancer Science*, **2021**, 112, 2770-2780	6.9	3
218	Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma. *Cancer Science*, **2021**, 112, 1225-1234	6.9	7
217	Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1 regulator. *Cancer Science*, **2021**, 112, 1614-1623	6.9	3
216	Development of a DELFIA method to detect oncofetal antigen ROR1-positive exosomes. *Biochemical and Biophysical Research Communications*, **2021**, 578, 170-176	3.4	0
215	Augmented oxidative stress increases 8-oxoguanine preferentially in the transcriptionally active genomic regions. *Free Radical Research*, **2020**, 54, 872-882	4	4
214	Overexpression of miR-199/214 is a distinctive feature of iron-induced and asbestos-induced sarcomatoid mesothelioma in rats. *Cancer Science*, **2020**, 111, 2016-2027	6.9	7
213	Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. *Nature Genetics*, **2020**, 52, 669-679	36.3	85
212	deficiency provides longer survival upon intraperitoneal crocidolite injection in female mice. *Free Radical Research*, **2020**, 54, 195-205	4	2
211	Tumor cell-derived angiopoietin-like protein 2 establishes a preference for glycolytic metabolism in lung cancer cells. *Cancer Science*, **2020**, 111, 1241-1253	6.9	7
210	Frequent homozygous deletion of Cdkn2a/2b in tremolite-induced malignant mesothelioma in rats. *Cancer Science*, **2020**, 111, 1180-1192	6.9	4
209	Method for Efficient Observation of Caveolin-1 in Plasma Membrane by Microscopy Imaging Analysis. *Methods in Molecular Biology*, **2020**, 2169, 43-52	1.4	
208	CERS6 required for cell migration and metastasis in lung cancer. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 11949-11959	5.6	8
207	ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma. *Oncogene*, **2019**, 38, 5142-5157	9.2	13
206	Divergent lncRNA MYMLR regulates MYC by eliciting DNA looping and promoter-enhancer interaction. *EMBO Journal*, **2019**, 38, e98441	13	16
205	Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy. *Journal of Surgical Oncology*, **2018**, 117, 947-956	2.8	6
204	Expression of P-REX2a is associated with poor prognosis in endometrial malignancies. *Oncotarget*, **2018**, 9, 24778-24786	3.3	2

203	Translating Gene Signatures Into a Pathologic Feature: Tumor Necrosis Predicts Disease Relapse in Operable and Stage I Lung Adenocarcinoma.. *JCO Precision Oncology*, **2018**, 2, 1-13	3.6	1
202	TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas. *Oncogene*, **2017**, 36, 3740-3748	9.2	17
201	Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells. *Cancer Science*, **2017**, 108, 1394-1404	6.9	27
200	Fenton reaction-induced renal carcinogenesis in Mutyh-deficient mice exhibits less chromosomal aberrations than the rat model. *Pathology International*, **2017**, 67, 564-574	1.8	12
199	Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas. *Cancer Science*, **2017**, 108, 1888-1896	6.9	20
198	Blood-borne miRNA profile-based diagnostic classifier for lung adenocarcinoma. *Scientific Reports*, **2016**, 6, 31389	4.9	10
197	Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells. *Journal of Clinical Investigation*, **2016**, 126, 254-65	15.9	34
196	ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. *Nature Communications*, **2016**, 7, 10060	17.4	54
195	ROR1 functions as a scaffold of cavin-1 and CAV1, sustaining caveolae and RTK-mediated survival signaling in lung cancer. *Journal of Thoracic Oncology*, **2016**, 11, S54-S55	8.9	
194	Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma. *Cancer Science*, **2016**, 107, 155-61	6.9	16
193	Mixture of Subspaces Image Representation and Compact Coding for Large-Scale Image Retrieval. *IEEE Transactions on Pattern Analysis and Machine Intelligence*, **2015**, 37, 1469-79	13.3	7
192	miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. *Carcinogenesis*, **2015**, 36, 1464-73	4.6	40
191	Cancer-promoting role of adipocytes in asbestos-induced mesothelial carcinogenesis through dysregulated adipocytokine production. *Carcinogenesis*, **2014**, 35, 164-72	4.6	16
190	BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors. *Oncogene*, **2014**, 33, 3803-11	9.2	22
189	Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features. *Carcinogenesis*, **2014**, 35, 2224-31	4.6	32
188	Image Classification Using a Mixture of Subspace Models. *IPSJ Transactions on Computer Vision and Applications*, **2014**, 6, 93-97	3.3	
187	Connective tissue growth factor and β-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma. *Journal of Pathology*, **2014**, 233, 402-14	9.4	26
186	Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. *International Journal of Cancer*, **2014**, 135, 308-18	7.5	50

185	Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages. *PLoS ONE*, **2014**, 9, e99568	3.7	49
184	Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. *Oncotarget*, **2014**, 5, 8252-69	3.3	40
183	Aberrant DNA replication in cancer. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2013**, 743-744, 111-117	3.3	15
182	The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. *Oncogene*, **2013**, 32, 3559-68	9.2	50
181	Cytotoxic interaction between amiodarone and desethylamiodarone in human peripheral lung epithelial cells. *Chemico-Biological Interactions*, **2013**, 204, 135-9	5	5
180	NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. *Cancer Cell*, **2013**, 23, 718-23	24.3	96
179	Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. *Fundamental and Clinical Pharmacology*, **2013**, 27, 557-69	3.1	89
178	SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers. *Scientific Reports*, **2013**, 3, 3012	4.9	18
177	Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis. *PLoS ONE*, **2013**, 8, e53087	3.7	51
176	Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. *PLoS ONE*, **2013**, 8, e57724	3.7	60
175	Inhibitory Effects of Salinomycin on Cell Survival, Colony Growth, Migration, and Invasion of Human Non-Small Cell Lung Cancer A549 and LNM35: Involvement of NAG-1. *PLoS ONE*, **2013**, 8, e66931	3.7	38
174	Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex. *PLoS ONE*, **2013**, 8, e79654	3.7	26
173	Hybrid liposomes affect cellular lipid constituents and caveolae structures. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1731-3	2.9	5
172	The ferroimmunomodulatory role of ectopic endometriotic stromal cells in ovarian endometriosis. *Fertility and Sterility*, **2012**, 98, 415-22.e1-12	4.8	23
171	Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. *PLoS ONE*, **2012**, 7, e43403	3.7	74
170	MYBPH inhibits NM IIA assembly via direct interaction with NMHC IIA and reduces cell motility. *Biochemical and Biophysical Research Communications*, **2012**, 428, 173-8	3.4	19
169	Iron overload signature in chrysotile-induced malignant mesothelioma. *Journal of Pathology*, **2012**, 228, 366-77	9.4	77
168	NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. *Cancer Cell*, **2012**, 21, 348-61	24.3	178

167	MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. *EMBO Journal*, **2012**, 31, 481-93	13	68
166	Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. *Cancer Research*, **2012**, 72, 1784-94	10.1	93
165	Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitis. *International Journal of Proteomics*, **2012**, 2012, 510397		3
164	A novel network profiling analysis reveals system changes in epithelial-mesenchymal transition. *PLoS ONE*, **2011**, 6, e20804	3.7	28
163	miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. *Cancer Research*, **2011**, 71, 6165-73	10.1	108
162	Guidelines for non-medical care providers to manage the first steps of emergency triage of elderly evacuees. *Geriatrics and Gerontology International*, **2011**, 11, 383-94	2.9	4
161	let-7 and miR-17-92: small-sized major players in lung cancer development. *Cancer Science*, **2011**, 102, 9-17	6.9	148
160	Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. *European Journal of Pharmacology*, **2011**, 651, 18-25	5.3	121
159	Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. *Molecular Carcinogenesis*, **2011**, 50, 301-9	5	32
158	Mechanisms of amiodarone and desethylamiodarone cytotoxicity in nontransformed human peripheral lung epithelial cells. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 336, 551-9	4.7	10
157	The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 44, 852-62	5.7	46
156	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *Journal of Thoracic Oncology*, **2011**, 6, 244-85	8.9	3178
155	Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, E1330-8	11.5	379
154	Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. *Laboratory Investigation*, **2010**, 90, 360-73	5.9	54
153	Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. *Nature Genetics*, **2010**, 42, 893-6	36.3	145
152	Regulation of DNA polymerase POLD4 influences genomic instability in lung cancer. *Cancer Research*, **2010**, 70, 8407-16	10.1	28
151	Novel metastasis-related gene CIM functions in the regulation of multiple cellular stress-response pathways. *Cancer Research*, **2010**, 70, 9949-58	10.1	17
150	Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. *Cancer Research*, **2010**, 70, 6059-70	10.1	69

149	Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. *Clinical Cancer Research*, **2010**, 16, 4401-10	12.9	80
148	Roles of POLD4, smallest subunit of DNA polymerase delta, in nuclear structures and genomic stability of human cells. *Biochemical and Biophysical Research Communications*, **2010**, 391, 542-6	3.4	28
147	Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. *American Journal of Pathology*, **2010**, 176, 1950-8	5.8	69
146	Functions of base selection step in human DNA polymerase alpha. *DNA Repair*, **2010**, 9, 534-41	4.3	10
145	Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. *PLoS ONE*, **2010**, 5, e11712	3.7	43
144	Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. *Cancer Research*, **2009**, 69, 4027-35	10.1	24
143	Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. *Journal of Clinical Oncology*, **2009**, 27, 2793-9	2.2	153
142	PCNA mono-ubiquitination and activation of translesion DNA polymerases by DNA polymerase {alpha}. *Journal of Biochemistry*, **2009**, 146, 13-21	3.1	13
141	Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. *Oncogene*, **2009**, 28, 3371-9	9.2	85
140	Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. *American Journal of Pathology*, **2009**, 175, 867-81	5.8	90
139	Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. *American Journal of Pathology*, **2009**, 175, 976-87	5.8	22
138	A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. *Oncology Research*, **2009**, 17, 581-91	4.8	13
137	Identification of Lung Cancer Metastasis Related Gene Expression Profile Using Combined Transcriptome Analysis. *Japanese Journal of Lung Cancer*, **2009**, 49, 902-909	0.1	
136	mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. *Respirology*, **2008**, 13, 510-7	3.6	26
135	Direct mitochondrial dysfunction precedes reactive oxygen species production in amiodarone-induced toxicity in human peripheral lung epithelial HPL1A cells. *Toxicology and Applied Pharmacology*, **2008**, 227, 370-9	4.6	22
134	Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. *Cancer Research*, **2008**, 68, 1647-55	10.1	73
133	Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. *Cancer Research*, **2008**, 68, 2106-11	10.1	120
132	Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. *Cancer Research*, **2008**, 68, 5540-5	10.1	262

131	let-7 regulates Dicer expression and constitutes a negative feedback loop. *Carcinogenesis*, **2008**, 29, 2073-7	4.6	181
130	Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. *Genes Chromosomes and Cancer*, **2008**, 47, 810-8	5	64
129	MicroRNAs in biological processes and carcinogenesis. *Carcinogenesis*, **2007**, 28, 2-12	4.6	206
128	Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. *Journal of Pathology*, **2007**, 212, 287-94	9.4	104
127	CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells. *Oncogene*, **2007**, 26, 4025-31	9.2	43
126	Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. *Oncogene*, **2007**, 26, 4600-8	9.2	36
125	Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. *Oncogene*, **2007**, 26, 6099-105	9.2	308
124	Inclusion of the ASH1 gene that governs the neuroendocrine differentiation of lung epithelium as an additional prototypic R lineage-survival oncogeneR *Nature Reviews Cancer*, **2007**, 7, 68-68	31.3	2
123	LKB1 gene mutations in Japanese lung cancer patients. *Cancer Science*, **2007**, 98, 1747-51	6.9	49
122	Expression profiling of genes regulated by TGF-beta: differential regulation in normal and tumour cells. *BMC Genomics*, **2007**, 8, 98	4.5	84
121	ESDN is a marker of vascular remodeling and regulator of cell proliferation in graft arteriosclerosis. *American Journal of Transplantation*, **2007**, 7, 2098-105	8.7	19
120	Aryl radical involvement in amiodarone-induced pulmonary toxicity: investigation of protection by spin-trapping nitrones. *Toxicology and Applied Pharmacology*, **2007**, 220, 60-71	4.6	15
119	Nongenomic beta estrogen receptors enhance beta1 adrenergic signaling induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human small airway epithelial cells. *Cancer Research*, **2007**, 67, 6863-71	10.1	39
118	A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. *Journal of the National Cancer Institute*, **2007**, 99, 858-67	9.7	63
117	Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. *Cancer Research*, **2007**, 67, 6007-11	10.1	168
116	Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. *Cancer Research*, **2007**, 67, 593-9	10.1	195
115	Novel NBS1 heterozygous germ line mutation causing MRE11-binding domain loss predisposes to common types of cancer. *Cancer Research*, **2007**, 67, 11158-65	10.1	26
114	hDREF regulates cell proliferation and expression of ribosomal protein genes. *Molecular and Cellular Biology*, **2007**, 27, 2003-13	4.8	52

113	Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. *International Journal of Cancer*, **2006**, 118, 1370-80	7.5	17
112	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. *Journal of Clinical Oncology*, **2006**, 24, 1679-88	2.2	257
111	Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. *American Journal of Pathology*, **2006**, 169, 1550-66	5.8	28
110	A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. *Journal of Molecular Diagnostics*, **2006**, 8, 335-41	5.1	162
109	Altered regulation of c-jun and its involvement in anchorage-independent growth of human lung cancers. *Oncogene*, **2006**, 25, 271-7	9.2	28
108	Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers. *Oncogene*, **2006**, 25, 6924-35	9.2	35
107	Protein Expression Profiling for Identification of Molecular Mechanism in Human NSCLC by Mass Spectrometry. *Japanese Journal of Lung Cancer*, **2006**, 46, 231-236	0.1	1
106	Theophylline stimulates cAMP-mediated signaling associated with growth regulation in human cells from pulmonary adenocarcinoma and small airway epithelia **2005**, 27, 155		1
105	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. *Journal of Clinical Oncology*, **2005**, 23, 2513-20	2.2	839
104	A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. *Cancer Research*, **2005**, 65, 9628-32	10.1	1330
103	EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. *American Journal of Surgical Pathology*, **2005**, 29, 633-9	6.7	206
102	Reduced expression of Dicer associated with poor prognosis in lung cancer patients. *Cancer Science*, **2005**, 96, 111-5	6.9	529
101	Throwing new light on lung cancer pathogenesis: updates on three recent topics. *Cancer Science*, **2005**, 96, 63-8	6.9	19
100	Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. *British Journal of Cancer*, **2005**, 93, 1157-67	8.7	51
99	Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines. *Molecular Carcinogenesis*, **2005**, 44, 233-41	5	24
98	ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. *Cancer Research*, **2005**, 65, 10680-5	10.1	97
97	Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. *Cancer Research*, **2005**, 65, 4739-46	10.1	332
96	Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines. *Cancer Research*, **2004**, 64, 4826-32	10.1	49

95	Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. *Journal of Clinical Oncology*, **2004**, 22, 811-9	2.2	136
94	Expression of CD109 in human cancer. *Oncogene*, **2004**, 23, 3716-20	9.2	71
93	Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. *Oncogene*, **2004**, 23, 4041-9	9.2	48
92	Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. *Oncogene*, **2004**, 23, 5360-70	9.2	120
91	Phenotypic composition of salivary gland tumors: an application of principal [corrected] component analysis to tissue microarray data. *Modern Pathology*, **2004**, 17, 803-10	9.8	14
90	CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. *Journal of Pathology*, **2004**, 203, 645-52	9.4	82
89	Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. *International Journal of Cancer*, **2004**, 112, 26-32	7.5	177
88	Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Research*, **2004**, 64, 3753-6	10.1	2077
87	Identification of MGB1 as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data. *Journal of Molecular Diagnostics* , **2004**, 6, 90-5	5.1	15
86	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer Research*, **2004**, 64, 8919-23	10.1	1059
85	K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. *American Journal of Pathology*, **2004**, 164, 91-100	5.8	65
84	Gene expression dose-response changes in microarrays after exposure of human peripheral lung epithelial cells to nickel(II). *Toxicology and Applied Pharmacology*, **2003**, 191, 22-39	4.6	39
83	RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. *International Journal of Cancer*, **2003**, 106, 45-51	7.5	53
82	Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. *International Journal of Cancer*, **2003**, 106, 198-204	7.5	76
81	Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. *International Journal of Cancer*, **2003**, 107, 341-5	7.5	43
80	Down-regulation of SKP2 induces apoptosis in lung-cancer cells. *Cancer Science*, **2003**, 94, 344-9	6.9	47
79	Prognostic models in patients with non-small-cell lung cancer using artificial neural networks in comparison with logistic regression. *Cancer Science*, **2003**, 94, 473-7	6.9	23
78	Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer. *Oncogene*, **2003**, 22, 1892-905	9.2	31

77	Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. *American Journal of Pathology*, **2003**, 163, 1109-16	5.8	101
76	Expression of cancer/testis (CT) antigens in lung cancer. *Lung Cancer*, **2003**, 42, 23-33	5.9	110
75	The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (Iressa) is not related to the expression of EGFR or HER-2 or to K-ras gene status. *Lung Cancer*, **2003**, 42, 35-41	5.9	62
74	Analysis of beta-tubulin gene alteration in human lung cancer cell lines. *Cancer Letters*, **2003**, 201, 211-6	9.9	14
73	Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. *Carcinogenesis*, **2003**, 24, 1581-92	4.6	34
72	Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. *Oncogene*, **2002**, 21, 2418-24	9.2	138
71	Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. *Oncogene*, **2002**, 21, 2328-33	9.2	110
70	Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo. *Oncogene*, **2002**, 21, 2822-8	9.2	45
69	Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis. *Oncogene*, **2002**, 21, 6884-97	9.2	112
68	Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. *Oncogene*, **2002**, 21, 7421-34	9.2	175
67	Lung cancer: an ever increasing store of in-depth basic knowledge and the beginning of its clinical application. *Oncogene*, **2002**, 21, 6868-9	9.2	14
66	Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential. *Oncogene*, **2002**, 21, 8310-9	9.2	29
65	Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. *Journal of the National Cancer Institute*, **2002**, 94, 819-25	9.7	425
64	Differential toxicogenomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin in malignant and nonmalignant human airway epithelial cells. *Toxicological Sciences*, **2002**, 69, 409-23	4.4	79
63	Differential inactivation of caspase-8 in lung cancers. *Cancer Biology and Therapy*, **2002**, 1, 65-9	4.6	122
62	TTF-1 expression in pulmonary adenocarcinomas. *American Journal of Surgical Pathology*, **2002**, 26, 767-73	3.7	307
61	Association between smoking habits and dopamine receptor D2 taqI A A2 allele in Japanese males: a confirmatory study. *Journal of Epidemiology*, **2002**, 12, 297-304	3.4	28
60	A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. *American Journal of Pathology*, **2002**, 161, 207-16	5.8	120

59	Identification of frequent G(2) checkpoint impairment and a homozygous deletion of 14-3-3epsilon at 17p13.3 in small cell lung cancers. *Cancer Research*, **2002**, 62, 271-6	10.1	22
58	Genetic diversity of drug targets including dihydropteroate synthase, dihydrofolate reductase and cytochrome b, in Pneumocystis carinii f. sp. hominis isolates in Japan. *Research Communications in Molecular Pathology and Pharmacology*, **2002**, 112, 159-76		2
57	The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. *Oncogene*, **2001**, 20, 3563-7	9.2	140
56	Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. *Oncogene*, **2001**, 20, 4228-34	9.2	58
55	Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. *American Journal of Pathology*, **2001**, 159, 1345-52	5.8	41
54	Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments. *American Journal of Pathology*, **2001**, 158, 87-96	5.8	29
53	Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers. *Cancer Letters*, **2001**, 162, 201-5	9.9	49
52	Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. *Genes Chromosomes and Cancer*, **2000**, 28, 342-6	5	45
51	Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers. *Oncogene*, **2000**, 19, 2305-11	9.2	44
50	Characterization of high-grade neuroendocrine tumors of the lung in relation to menin mutations. *Japanese Journal of Cancer Research*, **2000**, 91, 317-23		14
49	Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. *Japanese Journal of Cancer Research*, **2000**, 91, 865-8		188
48	Topographical distributions of allelic loss in individual non-small-cell lung cancers. *American Journal of Pathology*, **2000**, 157, 985-93	5.8	24
47	Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. *Annals of Thoracic Surgery*, **2000**, 70, 401-5; discussion 405-6	2.7	36
46	Frameshift mutations in TGFbetaRII, IGFIIR, BAX, hMSH3 and hMSH6 are absent in lung cancers. *Carcinogenesis*, **1999**, 20, 499-502	4.6	13
45	Risk factors for lung cancer among Northern Thai women: epidemiological, nutritional, serological, and bacteriological surveys of residents in high- and low-incidence areas. *Japanese Journal of Cancer Research*, **1999**, 90, 1187-95		13
44	Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. *Oncogene*, **1999**, 18, 4295-300	9.2	111
43	Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. *Oncogene*, **1999**, 18, 7180-3	9.2	50
42	Cloning and characterization of the alternative promoter regions of the human LIMK2 gene responsible for alternative transcripts with tissue-specific expression. *Gene*, **1999**, 236, 259-71	3.8	18

41	Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. *Research in Experimental Medicine*, **1998**, 197, 319-28		4
40	Molecular analysis of a Myc antagonist, ROX/Mnt, at 17p13.3 in human lung cancers. *Japanese Journal of Cancer Research*, **1998**, 89, 347-51		18
39	Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. *Oncogene*, **1998**, 17, 1743-7	9.2	146
38	Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. *Oncogene*, **1998**, 17, 2095-100	9.2	49
37	Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers. *Oncogene*, **1998**, 17, 3029-33	9.2	44
36	p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. *British Journal of Cancer*, **1998**, 77, 1568-72	8.7	25
35	Molecular cloning of human TAK1 and its mutational analysis in human lung cancer. *International Journal of Cancer*, **1998**, 75, 559-63	7.5	18
34	Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. *Lung Cancer*, **1998**, 20, 117-25	5.9	28
33	Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. *Journal of the National Cancer Institute*, **1998**, 90, 1563-8	9.7	43
32	Genomic structure of the human PLCD1 (phospholipase C delta 1) locus on 3p22-->p21.3. *Cytogenetic and Genome Research*, **1997**, 78, 58-60	1.9	9
31	Molecular cloning of CISH, chromosome assignment to 3p21.3, and analysis of expression in fetal and adult tissues. *Cytogenetic and Genome Research*, **1997**, 78, 209-12	1.9	21
30	In vitro effects of a recombinant toxin, mSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers. *Cancer Letters*, **1997**, 113, 153-8	9.9	3
29	Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. *Journal of Thoracic and Cardiovascular Surgery*, **1997**, 114, 354-60	1.5	47
28	Enhancement of artificial juxtacrine stimulation of insulin by co-immobilization with adhesion factors. *Journal of Biomedical Materials Research Part B*, **1997**, 37, 190-7		18
27	Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma **1997**, 18, 193-198		35
26	Subcellular localization and protein interaction of the human LIMK2 gene expressing alternative transcripts with tissue-specific regulation. *Biochemical and Biophysical Research Communications*, **1996**, 229, 582-9	3.4	24
25	Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. *Journal of Clinical Oncology*, **1996**, 14, 497-502	2.2	108
24	Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene. *Japanese Journal of Clinical Oncology*, **1996**, 26, 1-5	2.8	11

23	Differential expression of the c-kit proto-oncogene in germ cell tumours. *Journal of Pathology*, **1995**, 177, 253-8	9.4	125
22	Serum glutathione S-transferase-pi level as a tumor marker for non-small cell lung cancer. Potential predictive value in chemotherapeutic response. *Cancer*, **1994**, 73, 1377-82	6.4	25
21	Altered imprinting in lung cancer. *Nature Genetics*, **1994**, 6, 332-3	36.3	81
20	Expression of CD44 variant isoforms in normal and neoplastic cells of the lung. *Japanese Journal of Cancer Research*, **1994**, 85, 1112-6		17
19	Differential effect of p53 on the promoters of mouse DNA polymerase beta gene and proliferating-cell-nuclear-antigen gene. *FEBS Journal*, **1994**, 221, 227-37		31
18	Characterization of an 800 kb region at 3p22-p21.3 that was homozygously deleted in a lung cancer cell line. *Human Molecular Genetics*, **1994**, 3, 1341-4	5.6	43
17	Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin. *Journal of Virology*, **1994**, 68, 4656-61	6.6	50
16	Synchronous lung cancer presenting with small cell carcinoma and adenocarcinoma. *Chest*, **1993**, 104, 1602-4	5.3	12
15	Alterations of integrin expression in human lung cancer. *Japanese Journal of Cancer Research*, **1993**, 84, 168-74		27
14	Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer. *Molecular and Cellular Biology*, **1992**, 12, 1747-54	4.8	11
13	Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. *Journal of Virology*, **1992**, 66, 5100-5	6.6	113
12	Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. *Journal of Clinical Investigation*, **1992**, 89, 640-7	15.9	62
11	Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. *Journal of the National Cancer Institute*, **1991**, 83, 938-43	9.7	105
10	The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. *Nucleic Acids Research*, **1991**, 19, 4796	20.1	54
9	A chemical mismatch cleavage method useful for the detection of point mutations in the p53 gene in lung cancer. *American Journal of Respiratory Cell and Molecular Biology*, **1990**, 3, 405-11	5.7	12
8	Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. *Journal of Clinical Investigation*, **1990**, 86, 363-9	15.9	88
7	Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer. *International Journal of Cancer*, **1989**, 4, 32-4	7.5	13
6	p53: a frequent target for genetic abnormalities in lung cancer. *Science*, **1989**, 246, 491-4	33.3	1024

5	Chapter 24 Serological and biochemical analysis of four antigens associated with small cell lung cancer. *Lung Cancer*, **1988**, 4, 96-98	5.9	4
4	Use of the finite element method to determine epicardial from body surface potentials under a realistic torso model. *IEEE Transactions on Biomedical Engineering*, **1984**, 31, 611-21	5	59
3	Improvement of transportation in hospital. *Ningen Kogaku = the Japanese Journal of Ergonomics*, **1979**, 15, 111-116	0	1
2	48. Surgical Result for Glioma. *Neurologia Medico-Chirurgica*, **1965**, 7, 186a-186a	2.6	
1	Caffeine stimulates the proliferation of human lung adenocarcinoma cells and small airway epithelial cells via activation of PKA, CREB and ERK1/2. *Oncology Reports*,	3.5	2